Overexpression of visfatin/PBEF/Nampt alters whole-body insulin sensitivity and lipid profile in rats

References

• Kahn CR. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes. 1994; 43: 1066–84
   PubMed Web of Science ®Google Scholar
• Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus––a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996; 334: 777–83
   PubMed Web of Science ®Google Scholar
• Taylor SI. Insulin resistance or insulin deficiency: which is the primary cause of NIDDM?. Diabetes. 1994; 43: 735–40
   PubMed Web of Science ®Google Scholar
• Staiger H, Haring HU. Adipocytokines: fat-derived humoral mediators of metabolic homeostasis. Exp Clin Endocrinol Diab. 2005; 113: 67–79
   PubMed Web of Science ®Google Scholar
• Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedmen JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372: 425–32
   PubMed Web of Science ®Google Scholar
• Steppen CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409: 307–12
   Google Scholar
• Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med. 2001; 7: 941–6
   PubMed Web of Science ®Google Scholar
• Hug C, Lodish HF. Visfatin: A new adipokine. Science. 2005; 307: 366–7
   PubMed Web of Science ®Google Scholar
• Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005; 146: 1764–71
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307: 426–30
   PubMed Web of Science ®Google Scholar
• Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994; 14: 1431–7
   PubMed Web of Science ®Google Scholar
• Fukuhara, A, Matsuda, M, Nishizawa, M, Segawa, K, Tanaka, M, Kishimoto, K, , et al. Science. 2007;318:565. Retraction of: Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Science. 2005;307:426–30.
   Google Scholar
• Beltowski J. Apelin and visfatin: Unique ‘beneficial’ adipokines upregulated in obesity?. Med Sci Monit. 2006; 12: RA112–9
   PubMed Web of Science ®Google Scholar
• Berndt J, Kloting N, Kralisch S. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005; 54: 2911–16
   PubMed Web of Science ®Google Scholar
• Hammarstedt A, Pihlajamaki J, Sopasakis VR, Gogg S, Jansson PA, Laakso M, et al. Visfatin is an adipokine but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab. 2006; 91: 1181–4
   PubMed Web of Science ®Google Scholar
• Chen MP, Chung FM, Chang DM, Tsai JR, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006; 91: 295–9
   PubMed Web of Science ®Google Scholar
• Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre-B cell colony- enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006; 91: 3165–70
   PubMed Web of Science ®Google Scholar
• Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 2007; 67: 796–800
   PubMed Web of Science ®Google Scholar
• Yang G, Li L, Tang Y, Boden G. Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats: Possible role of the resistin and adiponectin. Biochem Biophys Res Commun. 2006; 339: 1190–6
   Google Scholar
• Hua Z, Xi Y, Naili W, Yaou Z, Guoping C. Macrostemonoside A promotes visfatin expression in 3T3-L1 cells. Biol Pharm Bull. 2007; 30: 279–83
   Google Scholar
• Scribner KB, McGrane MM. RNA Polymerase II association with the phosphoenolpyruvate carboxykinase (PEPCK) promoter is reduced in vitamin A-deficient mice. J Nutr. 2003; 33: 4112–7
   Google Scholar
• Miyazaki M, Kim YC, Ntambi JM. A lipogenic diet in mice with a disruption of the stearoyl-CoA desaturase 1 gene reveals a stringent requirement of endogenous monounsaturated fatty acids for triglyceride synthesis. J Lipid Res. 2001; 42: 1018–24
   PubMedGoogle Scholar
• Schweiger M, Schreiber R, Haemmerle G, Lass A, Fledelius C, Jacobsen P, et al. Adipose triglyceride lipase and hormone-sensitive lipase are the major enzymes in adipose tissue triacylglycerol catabolism. J Bio Chem. 2006; 286: 40236–41
   Google Scholar
• Shin DJ, Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SREBP-2). J Bio Chem. 2003; 278: 34114–8
   PubMed Web of Science ®Google Scholar
• Zeng L, Liao H, Liu Y, Lee TS, Zhu M, Wang X, et al. Sterol-responsive element-binding protein (SREBP) 2 down-regulates ATP-binding cassette transporter A1 in vascular endothelial cells. J Bio Chem. 2004; 279: 48801–7
   PubMed Web of Science ®Google Scholar
• Wahli W, Braissant O, Desvergne B. Peroxisome proliferators activated receptors: transcriptional regulation of adipogenesis, lipid metabolism and more. Chem Biol. 1995; 2: 261–6
   PubMed Web of Science ®Google Scholar
• Schoonjans K, Peinado Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996; 15: 5336–48
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem. 2001; 276: 41245–54
   PubMed Web of Science ®Google Scholar
• Berthiaume M, Sell H, Lalonde J, Gelinas Y, Tchernof A, Richard D, et al. Actions of PPARγ agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids. Am J Physiol Regul Integr Comp Physiol. 2004; 287: R1116–23
   Google Scholar
• Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005; 115: 1627–35
   PubMed Web of Science ®Google Scholar
• Wente W, Efanov AM, Brenner M, Kharitonenkov M, Köster A, Sandusky GE, et al. Fibroblast growth factor-21 improves pancreatic ß-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006; 55: 2470–8
   PubMed Web of Science ®Google Scholar